文献速递免疫规划传染病防控与疫情报告

BNT162b2 mRNA Covid-19疫苗在青少年中的安全性和有效性

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
PubMed 文献 · Vaccine · 2021-12-24

韩国对12年级学生自2021年7月19日起提供BNT162b2疫苗,10-11年级学生不符合条件。全国回顾性队列研究纳入444,313名首剂接种者,心肌炎和/或心包炎报告率首剂为每10万人1.8例(95%CI 0.8-3.5),第二剂为每10万人4.3例(95%CI 2.6-6.7);对有症状/无症状SARS-CoV-2感染的有效性首剂后14天为91.1%(95%CI 89.6-92.5),第二剂后14天为99.1%(95%CI 98.5-99.5)。

要点

  • 首剂接种者心肌炎和/或心包炎报告率为每10万人1.8例(95%CI 0.8-3.5)。
  • 第二剂接种者心肌炎和/或心包炎报告率为每10万人4.3例(95%CI 2.6-6.7)。
  • 疫苗对SARS-CoV-2感染的有效性首剂后14天为91.1%,第二剂后14天为99.1%。

核心结论

  • BNT162b2疫苗接种是安全的,并与SARS-CoV-2感染风险显著降低相关,提示青少年接种疫苗可能减轻Covid-19负担。

研究设计与样本

  • 全国性回顾性队列研究,纳入444,313名接种首剂BNT162b2疫苗的青少年。

主要发现

  • 首剂接种者心肌炎和/或心包炎报告率为每10万人1.8例(95%CI 0.8-3.5)。
  • 第二剂接种者心肌炎和/或心包炎报告率为每10万人4.3例(95%CI 2.6-6.7)。
  • 首剂接种后14天对有症状/无症状SARS-CoV-2感染的有效性为91.1%(95%CI 89.6-92.5)。
  • 第二剂接种后14天对有症状/无症状SARS-CoV-2感染的有效性为99.1%(95%CI 98.5-99.5)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10th-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. June Choe Y, Yi S, Hwang I, et al. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. 2021. PMID: 35012777. doi:10.1016/j.vaccine.2021.12.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。